Ketchum partners with MMG for extended healthcare product work

Ketchum has inked a new deal to bring MMG, an agency involved in patient enrollment for clinical trials, under its umbrella.

New York: Ketchum has inked a new deal to bring MMG, an agency involved in patient enrollment for clinical trials, under its umbrella. MMG will retain its identity and operate as a distinct business unit within Ketchum's group. Both companies are owned by Omnicom.

The agreement marks an intriguing partnership, with Ketchum's healthcare unit hoping it can boost its ability to serve healthcare clients as well as potentially impact when the agency is brought into the proceedings, according to Lorraine Thelian, senior partner at Ketchum. And with more clinical trials occurring outside of the U.S., Ketchum's international reach could strengthen MMG's offerings. MMG has expertise in oncology, endocrinology/cardiology, the central nervous system, as well as infectious and rare diseases.

“We're thrilled because obviously they are at the beginning of the healthcare pipeline in terms of when we have access to information,” Thelian said. “It's very important in understanding how to communicate to the patient audience as well as other groups crucial to drug development and safety.”

The Ketchum healthcare leadership team will remain in place, and MMG CEO John Benbrook will continue to lead his company, with a seven-member executive committee continuing to report to him.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.